IgG Light-chain Amyloidosis

This is a rare disease where the body makes too much of a protein called immunoglobulin light chain. These proteins build up in organs like the kidneys and heart, causing damage. It's caused by a problem with the plasma cells that make these proteins.

Condition

What people with IgG Light-chain Amyloidosis report

Every report comes from a Lived member, sent anonymously.

Have you tried Velcade (Bortezomib) for IgG Light-chain Amyloidosis?

NameHow it went

About IgG Light-chain Amyloidosis

What It Is

Immunoglobulin light chain amyloidosis, usually called AL amyloidosis (A for amyloid, L for light chain), is a rare disease in which a small group of abnormal plasma cells in the bone marrow makes too much of one antibody fragment, called a light chain. Healthy plasma cells make antibodies to fight infection. In AL amyloidosis, the excess light chains fold into the wrong shape and clump into tough fibers called amyloid. These deposits build up in organs, stiffen them and gradually stop them from working properly. The heart and kidneys are affected most often, followed by the liver, the digestive tract and the nerves. Heart involvement occurs in most people with the disease and is the main factor shaping how serious it is. Because symptoms depend on which organs are involved, the illness can look very different from one person to the next: tiredness and weight loss, breathlessness, swelling in the legs, numbness or tingling in the hands and feet, dizziness on standing, or diarrhea. Two signs are distinctive but uncommon: an enlarged tongue and easy bruising around the eyes. AL amyloidosis is one of several kinds of amyloidosis. Others, such as transthyretin (ATTR) amyloidosis, are made of different proteins and need different treatment, so confirming the exact type matters. AL amyloidosis is closely related to multiple myeloma, a cancer of plasma cells, and the two sometimes occur together.

Causes & Risk Factors

The direct cause is the abnormal group of plasma cells, which all descend from a single cell and make the same faulty light chain. Some light chains have small differences in their structure that make them unstable and likely to misfold. Why this clone of cells develops in a particular person is not known. AL amyloidosis is classed as a primary amyloidosis, as opposed to the hereditary forms passed down through families or the secondary forms caused by long-standing inflammation. The clearest risk factor is an existing plasma cell disorder. Monoclonal gammopathy of undetermined significance (MGUS) is a common, usually harmless finding of an abnormal antibody protein in the blood; people with MGUS have a higher chance of developing AL amyloidosis, although most never do. About 10 to 15 percent of people with multiple myeloma also have AL amyloidosis.

How It's Diagnosed

Diagnosis is often delayed by months or even years, because the early symptoms overlap with far more common conditions and people may see several specialists before amyloidosis is considered. Earlier diagnosis matters, especially when the heart is involved. Situations that should raise the question include heart failure with thickened heart walls that long-standing high blood pressure does not explain, protein leaking into the urine without diabetes or another clear cause, nerve damage with no clear cause, carpal tunnel syndrome in both wrists alongside heart problems, and any of these in someone already known to have MGUS or myeloma. The first tests look for the abnormal light chain. Immunofixation of blood and urine identifies an abnormal antibody protein, and a serum free light chain test measures the two types of light chain (kappa and lambda) and the ratio between them. An unbalanced ratio suggests one clone of cells is overproducing. A protein electrophoresis test on its own can miss AL amyloidosis, so all of these are done together. A positive result raises suspicion but does not confirm the disease, since many people with an abnormal protein have MGUS alone. Confirmation requires a biopsy showing amyloid in tissue, followed by laboratory typing to prove the amyloid is made of light chains rather than another protein. A small sample of belly fat taken with a needle or a tiny incision, combined with a bone marrow biopsy, often settles the question without a riskier biopsy of the heart or kidney. If those are negative and suspicion remains high, the affected organ itself is sampled. Once the diagnosis is made, every organ is checked. Blood tests for troponin and NT-proBNP (proteins released when heart muscle is damaged or strained), an echocardiogram (heart ultrasound) and sometimes a cardiac MRI show whether the heart is involved and how badly. Urine protein, kidney and liver tests complete the picture and determine the disease stage. A nuclear bone scan that can diagnose ATTR heart amyloidosis cannot diagnose the AL type, which is why the blood and urine light chain tests are essential whenever amyloid is suspected in the heart.

Treatment Options

Treatment has two aims that work together: shut down the supply of new amyloid by attacking the abnormal plasma cells, and support the organs that are already affected. It is usually led by a hematologist (blood specialist), ideally at a center with amyloidosis experience, working with heart and kidney specialists. The standard first treatment in the United States combines four medicines drawn from myeloma care: daratumumab (Darzalex Faspro, an antibody injected under the skin that targets plasma cells), bortezomib (a drug that disrupts how plasma cells handle proteins), cyclophosphamide (a chemotherapy drug) and dexamethasone (a steroid). In the main trial, adding daratumumab to the other three raised the share of people whose abnormal light chain could no longer be detected from about 13 percent to 42 percent, and over about five years it roughly halved the risk of the disease progressing, of major heart or kidney decline, or of death. This combination is not approved for people with the most advanced heart involvement outside a clinical trial. Serious heart problems occurred during treatment in the trial, so people with heart involvement are monitored more closely, and the medicines raise the risk of infection. Response is judged mainly by how far blood light chain levels fall, with the goal of a deep response. Organs recover more slowly than the blood tests. Function can keep improving for up to two years after light chain levels drop, even though the deposits themselves remain, so slow organ improvement in the first months does not by itself mean treatment is failing. For a minority of people, about 10 to 20 percent, high-dose chemotherapy with melphalan followed by an autologous stem cell transplant (a return of the person's own previously collected blood stem cells) is an option. When it succeeds, remission can last more than ten years, but treatment-related risk is significant, so it is reserved for people who are younger and fitter, without advanced heart or kidney disease. If the disease comes back or responds poorly, other myeloma drugs, venetoclax (a targeted pill not specifically approved for AL amyloidosis, used when the plasma cells carry a genetic change called t(11;14)) and newer immune therapies in clinical trials are possibilities. Drugs designed to clear amyloid already deposited in organs remain experimental. Supportive care runs alongside all of this. Fluid buildup from heart or kidney involvement is managed with diuretics (water pills) and fluid limits. Standard heart failure medicines such as beta-blockers can be poorly tolerated and are used cautiously, particularly when blood pressure is low. Other measures treat dizziness on standing, nerve pain and digestive problems, a pacemaker may be needed for heart rhythm problems, and dialysis can take over if the kidneys fail.

What to Expect

The outlook varies widely and depends mostly on how much the heart is affected when treatment starts. In one widely used staging system based on heart blood tests and light chain levels, about four in five people at the earliest stage are alive five years after diagnosis, compared with about one in five at the most advanced stage. Treatment has improved substantially over the past two decades, and people diagnosed before serious organ damage has developed can often live for many years. The first months of treatment are usually the most demanding, with frequent clinic visits, blood tests and adjustments to fluid and blood pressure medicines. Tiredness, swelling and breathlessness can limit activity, and some symptoms, such as nerve damage, may improve only partly. Keeping track of weight, swelling and blood pressure at home helps the care team adjust treatment. After initial treatment, light chain levels and organ tests are checked regularly for years. The disease can return, sometimes long after a good response, and further treatment is often effective when it does. Because AL amyloidosis is rare, care at or in contact with a specialized amyloidosis center, along with patient support organizations, can help people and families navigate decisions.

When to Seek Help

Ask about testing for AL amyloidosis if you have MGUS or myeloma and develop new swelling, breathlessness, numbness or protein in the urine, or if you have heart failure with thickened heart walls, unexplained kidney protein loss or unexplained nerve damage and no cause has been found. If you are being treated, contact your care team about sudden weight gain or new swelling, breathlessness that is worse than usual or comes on when lying down, dizziness or lightheadedness, new bleeding or bruising, or a fever or other sign of infection. Call 911 if you faint, feel severe chest pain, or have a fast, irregular heartbeat along with other symptoms, because heart involvement in AL amyloidosis can cause dangerous heart rhythms.

Questions to Ask Your Doctor

  1. 1.Which of my organs are involved, and what stage does that put me in?
  2. 2.Am I a candidate for the standard four-drug treatment or for a stem cell transplant, and what are the main risks for someone with my heart and kidney function?
  3. 3.How will we know whether treatment is working, and how long should I expect before my symptoms or organ function improve?
  4. 4.Should my care involve a specialized amyloidosis center, and is there a clinical trial I should consider?
  5. 5.Which symptoms should I track at home, and which ones should prompt me to call you?

Last reviewed • Oct 2026

Educational content, not medical advice.